Cargando…

Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study

BACKGROUND: Programmed death‐1 (PD‐1) blocking antibodies have been shown to improve progression‐free survival (PFS) and overall survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the objective response rate with these agents remains low, and the vast majority of NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ying, Mu, Di, Liu, Ting, Zhang, Huan, Zhang, Jiali, Li, Shuzhan, Wang, Rui, Du, Weijiao, Hui, Zhenzhen, Zhang, Xinwei, Ren, Xiubao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812069/
https://www.ncbi.nlm.nih.gov/pubmed/33150733
http://dx.doi.org/10.1111/1759-7714.13731
_version_ 1783637590223618048
author Han, Ying
Mu, Di
Liu, Ting
Zhang, Huan
Zhang, Jiali
Li, Shuzhan
Wang, Rui
Du, Weijiao
Hui, Zhenzhen
Zhang, Xinwei
Ren, Xiubao
author_facet Han, Ying
Mu, Di
Liu, Ting
Zhang, Huan
Zhang, Jiali
Li, Shuzhan
Wang, Rui
Du, Weijiao
Hui, Zhenzhen
Zhang, Xinwei
Ren, Xiubao
author_sort Han, Ying
collection PubMed
description BACKGROUND: Programmed death‐1 (PD‐1) blocking antibodies have been shown to improve progression‐free survival (PFS) and overall survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the objective response rate with these agents remains low, and the vast majority of NSCLC patients require alternative combination treatment regimens to prolong their survival. The purpose of this study was to evaluate the clinical efficacy of autologous cytokine‐induced killer (CIK) cell infusions combined with PD‐1 blocking antibodies in patients with NSCLC. METHODS: In this preliminary study, we investigated the safety and immune function effectiveness of PD‐1 blockade antibodies pembrolizumab or nivolumab administered in combination with or without autologous CIK cell infusions in 18 patients with advanced NSCLC. The peripheral blood mononuclear cells were isolated from these patients and the expression level of some cell surface molecules like PD‐1 were detected using flow cytometry to reflect the effectiveness of this combination regimen. RESULTS: No treatment‐related deaths occurred in either cohort. In comparison with the pretreatment level, CD3(+)CD56(+)CD16(+) T cells were significantly increased with the combination therapy, while myeloid‐derived suppressor cells were significantly increased with PD‐1 blocking antibody therapy alone but not with combination therapy. Although the serum interleukin‐4 level was downregulated following treatment with the combination regimen, interferon‐γ levels were unchanged. CONCLUSIONS: The purpose of this clinical study was to report the clinical efficacy and lack of exacerbated autoimmune adverse events with a combination of PD‐1 blockade and CIK cell infusions in patients with advanced NSCLC, further supporting assessments of this combination in future clinical trials.
format Online
Article
Text
id pubmed-7812069
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-78120692021-01-22 Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study Han, Ying Mu, Di Liu, Ting Zhang, Huan Zhang, Jiali Li, Shuzhan Wang, Rui Du, Weijiao Hui, Zhenzhen Zhang, Xinwei Ren, Xiubao Thorac Cancer Original Articles BACKGROUND: Programmed death‐1 (PD‐1) blocking antibodies have been shown to improve progression‐free survival (PFS) and overall survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the objective response rate with these agents remains low, and the vast majority of NSCLC patients require alternative combination treatment regimens to prolong their survival. The purpose of this study was to evaluate the clinical efficacy of autologous cytokine‐induced killer (CIK) cell infusions combined with PD‐1 blocking antibodies in patients with NSCLC. METHODS: In this preliminary study, we investigated the safety and immune function effectiveness of PD‐1 blockade antibodies pembrolizumab or nivolumab administered in combination with or without autologous CIK cell infusions in 18 patients with advanced NSCLC. The peripheral blood mononuclear cells were isolated from these patients and the expression level of some cell surface molecules like PD‐1 were detected using flow cytometry to reflect the effectiveness of this combination regimen. RESULTS: No treatment‐related deaths occurred in either cohort. In comparison with the pretreatment level, CD3(+)CD56(+)CD16(+) T cells were significantly increased with the combination therapy, while myeloid‐derived suppressor cells were significantly increased with PD‐1 blocking antibody therapy alone but not with combination therapy. Although the serum interleukin‐4 level was downregulated following treatment with the combination regimen, interferon‐γ levels were unchanged. CONCLUSIONS: The purpose of this clinical study was to report the clinical efficacy and lack of exacerbated autoimmune adverse events with a combination of PD‐1 blockade and CIK cell infusions in patients with advanced NSCLC, further supporting assessments of this combination in future clinical trials. John Wiley & Sons Australia, Ltd 2020-11-04 2021-01 /pmc/articles/PMC7812069/ /pubmed/33150733 http://dx.doi.org/10.1111/1759-7714.13731 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Han, Ying
Mu, Di
Liu, Ting
Zhang, Huan
Zhang, Jiali
Li, Shuzhan
Wang, Rui
Du, Weijiao
Hui, Zhenzhen
Zhang, Xinwei
Ren, Xiubao
Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
title Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
title_full Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
title_fullStr Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
title_full_unstemmed Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
title_short Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
title_sort autologous cytokine‐induced killer (cik) cells enhance the clinical response to pd‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: a preliminary study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812069/
https://www.ncbi.nlm.nih.gov/pubmed/33150733
http://dx.doi.org/10.1111/1759-7714.13731
work_keys_str_mv AT hanying autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT mudi autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT liuting autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT zhanghuan autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT zhangjiali autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT lishuzhan autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT wangrui autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT duweijiao autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT huizhenzhen autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT zhangxinwei autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy
AT renxiubao autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy